Long-term disability in anxiety disorders

Hendriks, Sanne M.; Spijker, Jan; Licht, Carmilla M.M.; Hardeveld, Florian; Graaf, Ron de; Batelaan, Neeltje M.; Penninx, Brenda W. J. H.; Beekman, Aartjan T.F.

doi:10.1186/s12888-016-0946-y

Cited by 71 publications

(39 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These disorders are associated with high societal costs (Kessler & Greenberg, 2002; Laynard, Clark, Knapp, & Mayraz, 2007), as well as significant decrements in psychosocial functioning and quality of life (Comer et al, 2011; Hendriks et al, 2016; Olatunji, Cisler, & Tolin, 2007). Fortunately, a sizable body of research has developed over the last several decades demonstrating cognitive behavioral therapy (CBT) to be an effective treatment for anxiety disorders (Hans & Hiller, 2013; Hofmann, Asnaani, Vonk, Sawyer, & Fang, 2012).…”

Section: Introductionmentioning

confidence: 99%

“…Anxiety disorders are the most prevalent class of mental disorders, with 12‐month prevalence rates of 21.3% in the United States (Kessler, Petukhova, Sampson, Zaslavsky, & Wittchen, ) and 11.6% worldwide (Baxter, Scott, Vos, & Whiteford, ). These disorders are associated with high societal costs (Kessler & Greenberg, ; Laynard, Clark, Knapp, & Mayraz, ), as well as significant decrements in psychosocial functioning and quality of life (QOL; Comer et al., ; Hendriks et al., ; Olatunji, Cisler, & Tolin, ). Fortunately, a sizable body of research has developed over the last several decades demonstrating cognitive behavioral therapy (CBT) to be an effective treatment for anxiety disorders (Hans & Hiller, ; Hofmann, Asnaani, Vonk, Sawyer, & Fang, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials

et al. 2018

View full text Add to dashboard Cite

The purpose of this study was to examine the efficacy of cognitive behavioral therapy (CBT) for anxiety-related disorders based on randomized placebo-controlled trials. We included 41 studies that randomly assigned patients (N = 2,843) with acute stress disorder, generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD), panic disorder (PD), posttraumatic stress disorder (PTSD), or social anxiety disorder (SAD) to CBT or a psychological or pill placebo condition. Findings demonstrated moderate placebo-controlled effects of CBT on target disorder symptoms (Hedges' g = 0.56), and small to moderate effects on other anxiety symptoms (Hedges' g = 0.38), depression (Hedges' g = 0.31), and quality of life (Hedges' g = 0.30). Response rates in CBT compared to placebo were associated with an odds ratio of 2.97. Effects on the target disorder were significantly stronger for completer samples than intent-to-treat samples, and for individuals compared to group CBT in SAD and PTSD studies. Large effect sizes were found for OCD, GAD, and acute stress disorder, and small to moderate effect sizes were found for PTSD, SAD, and PD. In PTSD studies, dropout rates were greater in CBT (29.0%) compared to placebo (17.2%), but no difference in dropout was found across other disorders. Interventions primarily using exposure strategies had larger effect sizes than those using cognitive or cognitive and behavioral techniques, though this difference did not reach significance. Findings demonstrate that CBT is a moderately efficacious treatment for anxiety disorders when compared to placebo. More effective treatments are especially needed for PTSD, SAD, and PD.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials

et al. 2018

View full text Add to dashboard Cite

show abstract

“…excessive fear, apprehension, disturbed concentration and sleep) and somatic (e.g. tachycardia, heart palpitations, sweating) symptoms, with arousal and avoidance behaviour thought to predict long-term disability [ 4 •, 5 ]. Symptom overlap among the different anxiety-related disorders and with other psychiatric diseases is a diagnostic challenge, while self-medication with alcohol and/or other drugs can progress to substance abuse and lead to significant co-morbidity between these diseases [ 4 •, 6 ].…”

Section: Anxiety- and Trauma-related Disorders And Their Treatment: Cmentioning

confidence: 99%

Cannabinoid Regulation of Fear and Anxiety: an Update

Papagianni

Stevenson

2019

Curr Psychiatry Rep

View full text Add to dashboard Cite

Purpose of Review Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings Evidence from preclinical studies has shown that the non-psychotropic phytocannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear by dampening its expression, enhancing its extinction and disrupting its reconsolidation. The findings from the relevant clinical literature are still very preliminary but are nonetheless encouraging. Summary Based on this preclinical evidence, larger-scale placebo-controlled clinical studies are warranted to investigate the effects of cannabidiol in particular as an adjunct to psychological therapy or medication to determine its potential utility for treating anxiety-related disorders in the future.

show abstract

“…After the pension decision, the psychotropic drug purchase level was higher for awarded applicants than rejected applicants, especially in the groups with major depressive and anxiety disorders. These disorder groups include a broad range of conditions with very different detriment on occupational ability (e.g., from mild to severe depression, from specific to generalized anxiety), and the severity of depression and anxiety predicts long-term disability [53][54][55]. Thus, if the health and pension systems are functional in demarcating the disabled from those with a less disabling condition, the broad range of symptom severity within depression and anxiety disorders may result in a clear difference between the awarded and rejected applicants in psychotropic drug consumption.…”

Section: Variation In Diagnostic and Sociodemographic Groupsmentioning

confidence: 99%

Consumption of psychotropic drugs among disability pension applicants with mental disorders: comparing awarded and rejected applicants in Finland

Perhoniemi

Tuulio‐Henriksson

Blomgren

et al. 2020

Soc Psychiatry Psychiatr Epidemiol

View full text Add to dashboard Cite

Purpose Psychotropic drug consumption as a proxy measure of mental health problems during a disability pension process has only been studied among awarded applicants. This study examined psychotropic drug purchase trajectories among awarded and rejected disability pension applicants. Analyses were conducted in different diagnostic and sociodemographic groups. Methods A representative 70% sample of Finnish adults applying for disability pension due to a mental disorder in 2009-2011 (N = 18,087) was followed for 4 years in 3-month periods both before and after the pension decision. Register data on purchased drugs measured in defined daily doses (DDDs), gender, age, occupational class, unemployment history, and diagnostic group were used. The DDD levels and trends were analyzed using growth curve models. Results Psychotropic drug purchases increased before the pension decision and decreased gradually thereafter among both awarded and rejected applicants. The average DDD level was higher for rejected than awarded applicants before the decision but lower thereafter. The high pre-decision level for rejected applicants was explicit with a lower socioeconomic status. The pre-decision increase in DDDs was steeper for awarded applicants. Changes in DDDs before and after the decision were most prominent for depression, bipolar disorders, schizophrenia, and anxiety disorders. Conclusion Awarded and rejected disability pension applicants differed partly in their trajectories of psychotropic drug consumption. For awarded applicants, the steep rise of consumption prior to the award possibly reflects worsening occupational capacity. Early high consumption for rejected applicants signals long running mental health problems and calls for earlier support.

show abstract

Long-term disability in anxiety disorders

Cited by 71 publications

References 43 publications

Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials

Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials

Cannabinoid Regulation of Fear and Anxiety: an Update

Consumption of psychotropic drugs among disability pension applicants with mental disorders: comparing awarded and rejected applicants in Finland

Contact Info

Product

Resources

About